← Eichor
Study identifier: NCT06984510 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Accelerated Biological Aging is Associated With Increased Risk of T2DM in the MASLD Population

Condition: Type 2 Diabetes Mellitus (T2DM) · Metabolic Dysfunction-Associated Steatotic Liver Disease · Biological Age  ·  Sponsor: Ningbo No. 1 Hospital

PhaseN/A
Planned participants2720
Who can joinAll sexes, 20 Years to 90 Years
Healthy volunteersNo

About this study

The association between biological aging and type 2 diabetes mellitus (T2DM) incidence in individuals with and without metabolic dysfunction-associated steatotic liver disease (MASLD) remains unclear.We assessed biological age by calculating phenotypic age (PhenoAge), Klemera-Doubal method (KDMAge), and homeostatic dysregulation (HDAge). To examine the association of biological ageing with the risk of T2DM, cox regression models were conducted. Furthermore, we applied survival analysis, restricted cubic spline models and population attributable fraction (PAF) to further evaluate the association between biological ageing and T2DM incidence.

This description comes directly from the study's public registry record.

Talk to the study team

Lei Xu  ·  +8613486659126  ·  xulei22@163.com

Always discuss trial participation with your own doctor first.

Locations (1)

the First Affiliated Hospital of Ningbo University Ningbo, Zhejiang, China, 315000Ningbo, Zhejiang, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06984510